Vertex Pharmaceuticals Inc (Vertex) is a biotechnology company that focuses on scientific innovation and establishing transformative medicines for serious diseases, particularly in specialty markets. The company has developed several approved medicines, including treatments for cystic fibrosis (CF), severe sickle cell disease (SCD), transfusion-dependent beta thalassemia (TDT), and moderate-to-severe acute pain. Vertex's clinical-stage pipeline includes programs targeting various diseases such as neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, type 1 diabetes, and myotonic dystrophy type 1.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Vertex invests in research and development (R&D) to discover and develop transformative medicines for people with serious diseases. The company's research strategy combines advances in understanding human disease and therapeutics. Vertex focuses on disease areas with known human biology, validated targets, predictive lab assays, and clinical biomarkers, aiming for transformative benefits regardless of modality. The company has successfully moved novel product candidates into clinical trials and obtained marketing approvals for several treatments, including those for cystic fibrosis, sickle cell disease, and acute pain. Vertex's approach includes advancing multiple candidates into clinical trials and pursuing multiple modalities to bring first-in-class or best-in-class therapies to patients. The company's development-stage product candidates target serious diseases, advancing multiple candidates into clinical trials and pursuing multiple modalities to bring first-in-class and/or best-in-class therapies to patients. The company's research and development strategy has been validated through success in moving novel product candidates into clinical trials and obtaining marketing approvals for five CF medicines, CASGEVY, and JOURNAVX. Vertex’s R&D units are responsible for the company's scientific discoveries and the development of innovative medicines. The R&D sites are in the US and the UK. The company focuses on potential therapies in the areas of alpha-1 antitrypsin deficiency (AATD), APOL1-mediated kidney disease (AMKD), autosomal dominant polycystic kidney disease (ADPKD), beta thalassemia, cystic fibrosis (CF), duchenne muscular dystrophy (DMD), IgA nephropathy (IgAN), myotonic dystrophy type 1 (DM1), pain, primary membranous nephropathy (pMN), sickle cell disease (SCD), and type 1 diabetes (T1D). A few of its pipeline products in Phase III include Inaxaplin to treat mediated kidney disease (AMKD); Povetacicept to treat IgA nephropathy (IgAN); and Suzetrigine to treat painful diabetic peripheral neuropathy. Drugs in phase II include Suzetrigine to treat painful lumbosacral radiculopathy, and Phase I drugs include VX-407 to treat autosomal dominant polycystic kidney disease (ADPKD). In FY2025, the company incurred R&D expenses of US$3,909.5 million, which as a percentage of revenue stood at 32.6%, and grew 7.7% YoY. As of December 2025, the company had 14 issued US patents that cover the active pharmaceutical ingredients in KALYDECO. It also had 22 issued US patents listed that cover the active pharmaceutical ingredients in ORKAMBI; 25 issued US patents that cover the active pharmaceutical ingredients in SYMDEKO; 34 issued US patents that cover the active pharmaceutical ingredients in TRIKAFTA; and 35 issued US patents that cover the active pharmaceutical ingredients in ALYFTREK.